Latest Breaking News On - Global vaccine business unit - Page 10 : comparemela.com

Search jobs Takeda Announces Approval of Moderna’s COVID-19 Vaccine in Japan - The Ministry of Health, Labour and Welfare (MHLW) Grants Regulatory Approval of Moderna’s COVID-19 Vaccine (COVID-19 Vaccine Moderna Intramuscular Injection) Following Positive Interim Results in Takeda’s Phase 1/2 Immunogenicity and Safety Clinical Trial - Interim Results Indicate Immune Response Consistent with Moderna’s Pivotal Phase 3 COVE Trial Results - Takeda Will Immediately Begin Distribution in Japan OSAKA, Japan, May 21, 2021  Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under article 14-3 of the Pharmaceuticals and Medical Devices Act for emergency use of Moderna’s mRNA COVID-19 vaccine, TAK-919, now known as COVID-19 Vaccine Moderna Intramuscular Injection, in Japan. The approval is based on positive clinical data from Takeda’s

United statesBiologika gmbRajeev venkayyaPlasma allianceTakeda pharmaceutical company limitedMinistry of healthJanssen pharmaceutical companies of johnsonInnovative medicines initiativeCovid rd allianceGovernment of japan ministry health labourJapan agency for medical researchGrants regulatory approvalModerna intramuscular injectionFollowing positive interim resultsSafety clinicalResults indicate immune response consistent